---
title: "Moleculin Biotech prices offering with warrants for 37,130,001 shares at $0.75 exercise price"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294525518.md"
description: "Moleculin Biotech priced a $9.3 million best-efforts public offering bundled with Common Warrants to purchase up to 37,130,001 shares at an exercise price of $0.75. The warrants are immediately exercisable and expire five years from the initial date. Net proceeds will advance Annamycin clinical development and support working capital, with closing expected around August 3, 2026."
datetime: "2026-07-31T14:12:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294525518.md)
  - [en](https://longbridge.com/en/news/294525518.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294525518.md)
generator: "portal-rs"
---

# Moleculin Biotech prices offering with warrants for 37,130,001 shares at $0.75 exercise price

-   Moleculin Biotech priced a $9.3 million best-efforts public offering bundled with Common Warrants to buy up to 37,130,001 shares. \* Common Warrants become immediately exercisable at USD 0.75 per share, expiring five years from the initial exercise date. \* Offering includes 12,376,667 common shares or pre-funded warrants at a combined price of USD 0.75 with associated warrants. \* Net proceeds earmarked to advance Annamycin clinical development, support working capital; closing expected around Aug. 3, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607311012PRIMZONEFULLFEED9801649) on July 31, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [MBRX.US](https://longbridge.com/en/quote/MBRX.US.md)

## Related News & Research

- [Moleculin Biotech highlights interim Phase 3 AML data for annamycin showing 36% CR, 54% CRc in pooled arms](https://longbridge.com/en/news/297668239.md)
- [Moleculin Biotech Updates Investors with New Presentation](https://longbridge.com/en/news/297565654.md)
- [Tiger Gold issues 25,619,351 units after special warrants are deemed exercised](https://longbridge.com/en/news/298136109.md)
- [ExpreS2ion sets warrant exercise price at SEK 1.6 per share](https://longbridge.com/en/news/297816638.md)
- [Nexera Technologies Resets Warrant Exercise Price to $1.6148 Effective September 3, 2026](https://longbridge.com/en/news/297973575.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**